Company Research Report: Approxima

Company Overview

• Name: Approxima

• Mission: Approxima is dedicated to developing a novel treatment for patients with tricuspid valve regurgitation (TR), a condition that affects over 13 million patients worldwide.

• Founding Details: No information is available.

• Key People:

• Dr. Paolo Denti: Chief Medical Officer

• Umberto Pasquali: Chairman of the Board

• Headquarters:

• Office: Viale Ortles 22/4, Milano 20139, Italy

• Registered Office: Via Amatore Sciesa 10, Seregno 20831, Italy

• Number of Employees: No information is available.

• Revenue: No information is available.

• Recognition: Approxima is known for its percutaneous tricuspid valve repair system, which offers a ventricular reshaping approach to treat tricuspid regurgitation.

Products

• Product Offered: Percutaneous Tricuspid Valve Repair System

• Description: This system uses a ventricular reshaping approach to repair the tricuspid valve without open-heart surgery. It is designed to address the physiological causes of tricuspid regurgitation, providing a minimally invasive treatment option.

• Key Features:

• Focuses on vulgar valve repair by addressing the underlying root cause of the condition.

• Physiological-like treatment through ventricle and annulus reshaping.

• Minimally invasive, offering a less risky alternative to traditional open-heart surgery.

Recent Developments

New Product Developments

• Preclinical Study Results: Recent preclinical results demonstrate the efficacy of Approxima’s technology in the treatment of TR, marking a significant milestone towards the first in-man clinical trial.

Scientific Board Expansion

• New Members:

• Prof. Nicolas Van Mieghem

• Dr. Federico De Marco

• These members are well-regarded interventional cardiologists who are supporting Approxima’s efforts into a fully percutaneous implantation procedure.

Conferences and Presentations

• EuroPCR 2024: Dr. Paolo Denti presented recent advancements of Approxima’s technology at the EuroPCR conference.

• PCR London Valve 2023: Approxima was acknowledged with a Top Innovation award, with preclinical data presented for the first time in a public setting.

Financial and Strategic Moves

• Seed Financing Round: Approxima raised €1.6 million in a seed financing round aimed at advancing its minimally invasive tricuspid valve repair technology.

• The round was led by Panakès Partners along with Club degli Investitori and several business angels.

Partnerships and Industry Recognition

• Industry Events:

• MedTech Innovator Road Tour 2024 in Dublin: Approxima was selected to showcase their technology.

• Awards: Applauded for innovation and contribution to medical technology, particularly in transcatheter heart valve therapies.

For further inquiries and contact, Approxima can be reached at info@approximamedical.com and remains active within their medical and technological community, including participation in significant global conferences such as MedTech Strategist Innovation Summit and EuroPCR.